Skip to Main Content

Publications Co-authored or Contributed to by Library Staff

Editing Services

Our Editing Services team currently employs 13 editors (including editorial managers), many with more than 25 years of editing experience. The editors perform both substantive editing and copy-editing of grant proposals, journal articles, and other materials. 

Literature Search Services

The Research Services team offers expertise on literature searching, systematic reviews and author and publication metrics to MD Anderson Cancer Center employees. We have years of combined searching experience using a variety of resources including MEDLINE, EMBASE, CINAHL, Web of Science, and many more.

Legend

Symbol Definition
Editing Publications that have been edited.
Searching Publications that have had searching assistance.
Co-Authorship Publications with library co-authors.
Star Publications with two or more types of contributions.

Publications Co-authored or Contributed to by Library Staff

In fiscal year 2021-2022, Research Medical Library staff have co-authored or been acknowledged for their contributions to the following publications. Names of library co-authors are in bold; for publications without a library co-author, the specific library contribution (e.g., Literature Searching; Editing) is noted. View a full list of 2020 contributions.

2022 RML Contributed Publications

RML publications by years

August 2023

Contribution Citation Altmetric Badge
Editing

Jayan A, Raghavendra AS, Bassett R, Barcenas CH. Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis. Clin Breast Cancer. 2023 Aug 29.

 
Editing

Ejezie CL, Savas LS, Durand C, Shegog R, Cuccaro P. The Prevalence of HPV Vaccination among Racial/Ethnic Minority Adolescents During the COVID-19 Pandemic. JNCI Cancer Spectr. 2023 Aug 31.

 
Editing

Szymanowska A, Rodriguez-Aguayo C, Lopez-Berestein G, Amero P. Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment. Non-Coding RNA. 2023 Aug 28;9(5):52.

 
Editing

Dimopoulos YP, Kwon D, Milton DR, et al. Assessing the Impact of the COVID-19 Pandemic on Training at the MD Anderson Cancer Center Anatomical Pathology Fellowship Program. Arch Pathol Lab Med. 2023 Aug 28.

 
Editing

Jain AJ, Maxwell JE, Katz MH, Snyder RA. Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma. Cancers (Basel). 2023 Aug 19;15(16):4174.

 
Editing

Sharma P, Borthakur G. Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia. Cancer Drug Resistance. 2023 Aug 17.

 
Co-Author and Editing

Salama V, Geng Y, Rigert J, Fuller CD, Shete S, Moreno AC. Systematic Review of Genetic Polymorphisms Associated with Acute Pain Induced by Radiotherapy for Head and Neck Cancers. Clin Transl Radiat Oncol. 2023 Aug 28.

 
Editing

Qiqi Y, Hui C, Cody H, et al. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. 2023 Aug 16.

 
Editing

Liu Y, Wei D, Deguchi Y, et al. PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric Cancer. 2023 Aug 12.

 
Editing

Liu X, Zhuang L, Gan B. Disulfidptosis: disulfide stress-induced cell death. Trends Cell Biol. 2023 Aug 12;S0962-8924(23)00141-1.

 
Editing

Salvo G, Flores Legarreta A, Ramalingam P, et al. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study. Int J Gynecol Cancer. 2023 Aug 10.

 
Editing

Liu J, Yu Q, Wang XS, et al. Compound Kushen Injection Reduces Severe Toxicity and Symptom Burden Associated With Curative Radiotherapy in Patients With Lung Cancer. J Natl Compr Canc Netw. 2023 Aug;21(8):821-830.e3.

 
Editing

Contrera KJ, Phan J, Waguespack SG, et al. Prevalence of pituitary hormone dysfunction following radiotherapy for sinonasal and nasopharyngeal malignancies. Head Neck. 2023 Aug 3.

 
Editing

Chen H, Ding Q, Khazai L, et al. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023 Aug 2;15:17588359231189422.

 
Editing

Huang M, Yao F, Nie L, et al. FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways. Mol Cell. 2023 Aug 3;83(15):2810-2828.e6.

 
Editing

Maki H, Kim BJ, Kawaguchi Y, et al. Incidence of and Risk Factors for Incisional Hernia After Hepatectomy for Colorectal Liver Metastases. J Gastrointest Surg. 2023 Aug 3. 2023 Jul;5(4):e230009.

 

July 2023

Contribution Citation Altmetric Badge
Editing

Moises M-C, Hamoda A, Paola A, Cristian R-A. Immune Modulatory Long-Non-Coding RNA as a Potential Therapeutic Target in Cancer. Preprints. 2023 Jul 07. 2023070447.

 
Editing

Hwang K-P, Elshafeey NA, Kotrotsou A, et al. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiol Imaging Cancer. 2023 Jul;5(4):e230009.

 
Editing

Schwartz-Duval A, Mackeyev Y, Gagea M, Krishnan S, Sokolov K. Biogeochemistry concepts in medicine: Radiosensitizing pancreatic cancer through pathology driven biosynthesis of gold nanoparticles. ChemRxiv. 2023 Jul 26.

 
Editing

Sun H, Ding Q, Sahin AA. Immunohistochemistry in the Diagnosis and Classification of Breast Tumors. Arch Pathol Lab Med. 2023 Jul 25.

 
Editing

Sun P, Wei P, Liu H, et al. GWAS-identified telomere length associated genetic variants predict risk of recurrence of HPV-positive oropharyngeal cancer after definitive radiotherapy. EBioMedicine. 2023 Jul 22;94:104722.

 
Editing

Amit M, Baruch E, Nagarajan P, et al. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade. Res Sq. 2023 Jul 18.

 
Editing

Altan M, Soto F, Xu T, et al. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clin Oncol. 2023 Jul 14.

 
Editing

Huang ML, Tomkovich K, Lane DL, Katta R, Candelaria RP, Santiago L. Breast Cancer Cryoablation Fundamentals Past and Present: Technique Optimization and Imaging Pearls. Acad Radiol. 2023 Jul 15.

 
Editing

Jin D, Chen H, Zhou M-H, Chen S-R, Pan H-L. mGluR5 from primary sensory neurons promotes opioid-induced hyperalgesia and tolerance by interacting with and potentiating synaptic NMDA receptors. J Neurosci. 2023 Jul 13;JN-RM-0601-23.

 
Editing

Cuglievan B, Connors J, He J, et al. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia. 2023 Jul 14.

 
Editing

Sobhani N, Tardiel-Cyril DR, Chai D, et al. Artificial Intelligence-Powered Discovery of Small Molecules Inhibiting CTLA-4 in Cancer. Research Square. 2023 10 Jul.

 
Co-Author and Editing

Cho D, Kim S, Mama SK, Swartz MC, Geng Y, Lu Q. Multiple Levels of Influence on Lifestyle Behaviors among Cancer Survivors in Racial and Ethnic Minority Groups: A Systematic Review. European Journal of Cancer Care. 2023 13 Jul.

 
Editing

Radaram B, Glazer SE, Yang P, et al. Evaluation of 89Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET. ACS Omega. 2023 May 4;8(19):17181-17194.

 
Editing

Fukuda Y, Kim S-H, Bustos MA, et al. Inhibition of microsomal prostaglandin E2 synthase reduces collagen deposition in melanoma tumors and may improve immunotherapy efficacy by reducing T cell exhaustion. Cancer Res Commun. 2023 Jul 07.

 
Editing

Giraudier S, Gou P, Liu D, et al. Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms. Research Square. 2023 Jul 06.

 
Editing

Mehmet A, Yan W, Juhee S, et al. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer. 2023 Jul;11(7):e006871.